Zai Lab Limited American Depositary Shares Investor update

Thank you, Rafael. Now I will be presenting results from the phase I study evaluating zoci in combination with atezo plus or minus carboplatin, what we call it doublet or triplet cohort. On this slide, we can see our study design, which includes dose escalation and backfill and expansion cohorts for the doublet combination, zoci plus atezo. As you can see also here, we will focus on what we have in the red squares on the backfill expansion for the doublet, and we also present some results on the triplet. On the next slide, we can see the baseline characteristics for the population included. About three-quarters at stage 4 disease at initial diagnosis. Most were ECOG 1, and this perhaps reflect that usually these patients are symptomatic and need treatment that can reduce the tumor burden.

Also, highly important will be the presence of brain metastasis, that as a reminder, this study includes the patients with untreated brain metastasis. The doublet population was predominantly Asian, while the triplet was more balanced. This was related perhaps with the initial study that includes a lot of patients from Asia. It is true that if we take into account the study and also the efficacy on second-and-plus lines from zoci, we have not observed a difference in efficacy or safety between Asian and non-Asian patients. Also here, highlighting that for the first 15 patients treated with 1.6 mg/kg doublet, the median follow-up was 10 months. At the 1.2 mg/kg dose level, the median follow-up was 12.6 months. With that context, the next slide, we can see the waterfall plot for the doublet first-line combination.

As you can see here, these three slides show the efficacy from zoci plus atezolizumab first line. Overall, the confirmed objective response rate was 81.4%, and nearly all patients had a response of stable disease. In particular, among the 33 patients treated with zoci at 1.6 mg/kg in combination with atezo, 27 patients achieved a confirmed response, an objective response rate of 81.80%. Taking account the standard of care, chemo plus immunotherapy, this compares favorably with, for the standard of care, we can think about a 60%-68% of response rate. On the next slide, we can also see a spider plot where we are seeing those responses occur early. This is also something that is clinically relevant. Of 35 responders, 34 achieved their response at the first post-baseline tumor assessment. So what we are seeing is a very rapid onset of response with this combination.

Importantly, as you can see with some arrows, those responses are still ongoing. If we put it, again, in context of the standard of care that we have currently, usually the patients with small cell lung cancer, the disease progress quickly within the first 5 months. So this is something that is very positive from this combination. For the 10 patients treated with 1.2 mg/kg, the duration of response was 8.3 months. For the first 15 patients at 1.6 mg/kg with a minimum of 10 months of follow-up, the median duration of response was not reached. So this is very encouraging results. The progression-free survival for 33 patients at 1.6 mg/kg cohort, the 6 months progression-free survival was 81.9%, which is a very promising result.

For the first 15 patients with longer follow-up, median progression-free survival has not yet been reached, and two-thirds of those patients have not progressed as of cutoff. The 18 additional patients in the expansion cohort demonstrated an encouraging early progression-free survival consistent with the initial 15 patients. For reference, the 6 months progression-free survival with chemo immunotherapy in the IMpower133 was around 30%. Clearly, these results could change how we think about the first-line small cell lung cancer treatment. On the next slide, we also evaluate the zoci as a triplet in combination with atezo plus carboplatin. Despite the small sample size, we can see a very notable anti-tumor activity with a confirmed objective response rate of 92.3%. As you can see, important tumor reduction with patients achieving almost a complete response.

This is, again, as in the doublet, this tumor reduction is quite important in our patients that most of the times are very symptomatic at diagnosis. Again, if you look at the durability of this tumor reduction with a triplet, we can also see this is observed within the first tumor assessment, so very rapid, deep, again, with a sustained tumor reduction with a triplet. On the next slide, also important is the safety as a doublet, as a first-line therapy. So the favorable tolerability we have observed with zoci monotherapy previously in patients with second-and-plus lines has continued to be encouraging in this first-line doublet. There are no dose-limiting toxicities observed during dose escalation. At 1.6 mg/kg in 33 patients, only 9.1% of patients experienced Grade 3 or higher adverse events attributed to zoci.

We only observed one case of Grade 1 ILD. This is relevant in the context of other ADCs in the field in small cell lung cancer that we are seeing higher rates of ILD. There were no zoci-related treatment discontinuations or treatment-related deaths reported in this cohort. This is something that deserves to be highlighted compared with other drugs currently being explored in small cell. Although it is also true that these data are still maturing, I believe that the zoci safety profile will be consistent with what we have seen in zoci monotherapy, where we have a longer follow-up. As the conclusions in the doublet part, it seems that adding atezolizumab does not seem to change the safety profile of zoci. On the next slide, we have the safety of the triplet as first-line therapy.